Free Trial
NASDAQ:IFRX

InflaRx Q2 2023 Earnings Report

InflaRx logo
$1.76 -0.09 (-4.59%)
As of 09:47 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

InflaRx EPS Results

Actual EPS
-$0.15
Consensus EPS
-$0.36
Beat/Miss
Beat by +$0.21
One Year Ago EPS
N/A

InflaRx Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

InflaRx Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Thursday, August 10, 2023
Conference Call Time
5:00AM ET

Upcoming Earnings

InflaRx's Q1 2025 earnings is scheduled for Wednesday, May 7, 2025, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

InflaRx Earnings Headlines

Cantor Fitzgerald Begins Coverage on InflaRx (NASDAQ:IFRX)
InflaRx (IFRX) to Release Earnings on Wednesday
Trump to solve American wealth loss?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve suffered financial hardship…Our President may have solved everything.
InflaRx to Report First Quarter 2025 Results on May 7, 2025
See More InflaRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like InflaRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on InflaRx and other key companies, straight to your email.

About InflaRx

InflaRx (NASDAQ:IFRX) N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

View InflaRx Profile

More Earnings Resources from MarketBeat